Cullinan Therapeutics, Inc. (CGEM)
10.28
+0.09
(+0.88%)
USD |
NASDAQ |
Nov 13, 16:00
10.26
-0.02
(-0.19%)
After-Hours: 19:59
Cullinan Therapeutics Debt to Equity Ratio : 0.0071 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.0071 |
| June 30, 2026 | 0.0064 |
| March 31, 2026 | 0.0065 |
| December 31, 2025 | 0.0066 |
| September 30, 2025 | 0.0026 |
| June 30, 2025 | 0.0031 |
| March 31, 2025 | 0.0033 |
| December 31, 2024 | 0.0036 |
| September 30, 2024 | 0.0039 |
| June 30, 2024 | 0.0042 |
| March 31, 2024 | 0.0074 |
| December 31, 2023 | 0.0079 |
| September 30, 2023 | 0.0126 |
| June 30, 2023 | 0.0088 |
| Date | Value |
|---|---|
| March 31, 2023 | 0.0097 |
| December 31, 2022 | 0.0094 |
| September 30, 2022 | 0.008 |
| June 30, 2022 | 0.0019 |
| March 31, 2022 | 0.003 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Climb Bio, Inc. | 0.0047 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6888 |
| Anixa Biosciences, Inc. | 0.012 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 322.56M |
| Total Liabilities (Quarterly) | 41.28M |
| Shareholders Equity (Quarterly) | 281.28M |
| Current Ratio | 7.430 |
| Net Debt Paydown Yield | -0.01% |